Lab Data Integrity Conference

18-19 October 2017, Barcelona, Spain

Course No. 16028



Gunnar Danielson, Mettler Toledo GmbH, Switzerland

Dr Markus Dathe, F. Hoffmann-La Roche, Switzerland

Travis Frick, GlaxoSmithKline Vaccines, Belgium

Dr Bob McDowall, ECA Data Integrity Working Group, R D McDowall Ltd

Dr Danilo Neri, PQE, Italy

Dr Siegfried Schmitt, PAREXEL International, UK

Dr Franz Schönfeld, GMP Inspector, Government of Upper Franconia, Germany


Data integrity in the GMP analytical laboratory continues to be THE major global topic amongst both regulatory agencies, pharmaceutical companies and suppliers. Although the headlines are still gabbed by warning letters and non-compliances involving cases of falsification and fraud from a minority of organisations this is the tip of the iceberg. The majority of data integrity issues seen in warning letters and 483 observations are still due to poor data management practices where records created are not adequately documented, electronic records that are poorly protected or not protected at all and / or there is still a reliance on paper printouts from computerised systems as raw data.

Since 2015 there has been a tsunami of regulatory guidance and advice from MHRA, FDA, WHO, PIC/S, EMA and even the Chinese FDA. In addition, ECA have issued a draft guidance for comment and the April 2017 release of the GAMP guidance on Records and Data Integrity that is a companion to GAMP 5. Do these guidances say the same things or are there contradictions? How should laboratories and suppliers respond to the WHO suggestion that „replacement of
hybrid systems should be a priority“?

The second Laboratory Data Integrity conference is designed to present, from a practical
perspective, the following areas:

  • Laboratory data integrity where are we now?
  • Regulator talk
  • Review of the GAMP Guide on Records and Data Integrity
  • Scope of the Second person review
  • Instruments with integrated software – quo vadis?
  • Data integrity audits
  • Data integrity from research to manufacturing
  • Developing metrics for laboratory data integrity
  • Using data flow mapping to identify data integrity concerns
  • Instrument Supplier’s perspective of data integrity
In addition, there will be a Discussion Forum at the end of day 1 where all delegates will have the opportunity to ask specific questions to benefit from the speakers’ experiences in this field.

Target Group

The conference is intended for the technical and managerial personnel who deal with data integrity issues including analytical development and quality control analytical laboratories in pharmaceutical companies, contract research and manufacturing organisations. QA personnel responsible for quality oversight of data integrity work will also find the conference invaluable.


Introduction – Laboratory Data Integrity: Where Are We Now?

  • Overview of data integrity since October 2016 conference
  • Warning letter update
  • Regulatory guidance update
  • GAMP Guide on Records and Data Integrity
Regulatory Requirements and Expectations
  • Legal requirements, European and international guidelines and guidance documents
  • Case study: data integrity in the quality control lab and how it relates to the continuous
  • improvement process
  • Inspection findings
Mitigating Data Integrity Risks in Pharmaceutical Manufacturing
  • What is “data integrity”?
  • What is “metadata”?
  • What primary data integrity risks are associated with data systems (paper, electronic,
  • and hybrid)? How can these risks be mitigated?
  • How can manipulation of electronic records be detected?
  • What are the requirements of/best practices for validating a computer system/
  • electronic records?
  • What are the most important things for companies to do or recognize regarding
  • manufacturing data integrity?
Metrics for Laboratory Data Integrity
  • What are metrics?
  • Metrics will change throughout a data integrity programme: assessment and
  • remediation phases
  • Suggested metrics for routine chemical analysis
Case Study: Data Integrity from Research to Manufacturing: Balancing Analytical
Science and Regulatory Compliance

  • Patient safety, freedom of research and speed to market: the dilemma of development
  • DI in the development lifecycle – phase appropriate requirements
  • Is it just regulations or common sense?
  • The TITO principle and how to avoid it
  • Benefits of data integrity measures
  • Data ownership as a key prerequisite for DI compliance
Instruments with Integrated Software and Data Integrity
  • The new USP <1058> and the Lab Instrument classes
  • The class B and Data Integrity
  • The hubris of hybrids – paper complicates everything!
  • Criticality: how critical is critical?
Scope and Detail of a Second Person Review
  • US and EU regulatory requirements for second person review
  • Responsibilities and SOP for the review
  • Key requirement for the review: objective evidence
  • Paper record review
  • Hybrid system review problems
  • Electronic system set up – is the software up to the job?
  • Assays where second person review can be problematic
Using Data Flow Mapping to Identify Data Integrity Concerns
  • What is ‘Data Flow Mapping’?
  • How to execute ‘Data Flow Mapping’?
  • The benefits of ‘Data Flow Mapping’
  • Examples of ‘Data Flow Mapping’ detecting data integrity concerns
Data Integrity: An Instrument Suppliers Perspective
  • The extent to which all data are complete, consistent and accurate throughout the
  • data lifecycle“ – the lifecycle starts at the beginning – at the source of the data
  • It‘s about the controls throughout the whole process
  • Common misconceptions of benchtop instruments
  • Start with correct data – finish well.
Data Integrity Audits – An Analytical Perspective
  • What to expect when preparing an audit for data integrity
  • The analytical laboratory - from the clinical setting to the certified laboratory
  • (50 shades of grey?)
  • How to plan the audit (access to site, systems and records; length of audit, location
  • of audit, etc.)
  • Performing the audit (access to staff, access to systems and records - let the hunt begin!)
  • From black holes to compliant records - where to draw the line?
  • The audit report - explaining the unexplainable, the difficult and the obvious
Review of the GAMP Guide: Records and Data Integrity
  • Overview of the new guide
  • Review and Discussion of key sections of the Guide: Data governance framework
  • Data life cycle, Risk management, Management, development and operation appendices
Laboratory Control Systems: how to prevent Data Integrity violations
  • Strongly enforced Data Integrity Requirements in the latest 3 years by almost every
  • Regulated Agency in the latest guidances issued by MHRA, WHO, FDA and recently
  • by PIC/S.
  • Particularly importance in the laboratory environment where data created within the
  • analytical processes are relied upon to ensure the Product Quality
  • Requirement to implement every control measure oriented to prevent Data Integrity
  • violation either through automatic functionalities and interim manual procedures
  • Need to routinely monitor the effectiveness of these measures in pharmaceutical
  • companies


This course is part of the GMP Certification Programme "ECA Certified Data Integrity Manager" Learn more

This training/webinar cannot be booked. Send us your inquiry by using the following contact form.

To find alternative dates for this training/webinar or similar events please see the complete list of all events.

For many training courses and webinars, there are also recordings you can order and watch any time. Just take a look at the complete list of all recordings.

* also payable by credit card
American Express Visa Mastercard

Further dates on-site
Further dates on-site
Not available
Further dates online
Further dates online
Not available
Not available

Do you have any questions?

Please contact us:
Tel.: +49 6221 8444-0

Woman with headset

Go back

Testimonials about our courses and conferences

“Fantastic course – I really enjoyed the interactive structure & greatly appreciate social activity.”

Anthony Cummins, Sebela Pharmaceuticals, Ireland
GMP Auditor Practice, September 2023


“Very well organized, information on point without being overwhelming.”

Eleni Kallinikou, Pharmathen
Live Online Trainng - Pharmaceutical Contracts - Febuary 2024


“Good overview of different types of agreements, good to see both the GMP and the legal angle”

Ann Michiels, Johnson&Johnson
Live Online Trainng - Pharmaceutical Contracts, Febuary 2024



“Well prepared presentations and good presenters. I also like the way of asking questions.”

Alexandra Weidler, Hookipa Biotech GmbH, Austria
Live Online Training – QP Education Course Module A, November 2023